Finding new life: Young pharma, biotech firms offer second chance for New Jersey’s legacy R&D space

A growing pipeline of young life sciences firms has offered a second chance for New Jersey’s stock of legacy laboratory space. In the process, the ventures have served as anchors for developers seeking to repopulate large, vacant pharmaceutical campuses with turnkey laboratories.

Rutgers, Monmouth students set to weigh in on Roche campus at NAIOP program

Less than a month after hosting a forum for local residents and other stakeholders, the former Hoffmann-LaRoche campus will welcome aspiring commercial real estate professionals.

High hopes for life sciences

For all the time we’ve spent highlighting New Jersey’s glut of sprawling, vacant corporate campuses, it’s easy to lose sight of just how many of them have been rescued in recent years by some of the state’s boldest and most inventive developers. Those success stories are worth telling, which is why we often do at Real Estate NJ. But there are underlying trends or nuances in some of those projects that don’t get as much attention on a day-to-day basis. Like how a crop of innovative, lesser-known biotech and pharmaceutical firms are backfilling space at the former research campuses of Sanofi and Hoffmann-LaRoche, helping to stabilize those sites as their new owners pursue larger redevelopment plans.

Quest, Ralph Lauren eye projects at ex-Roche campus on Route 3

Quest Diagnostics and Ralph Lauren could be among the newest tenants at the former Hoffmann-LaRoche campus in Clifton and Nutley, now known as ON3, following the approval of $88 million in tax credits to support more than 500,000 square feet of activity at the site.